Leveraging ctDNA/MRD Testing in Breast Cancer Management

Marla D. Lipsyc-Sharf, MD, highlights the clinical evolution of the Signatera Genome test for residual disease surveillance in patients with breast cancer.

Marla D. Lipsyc-Sharf, MD, discusses the evolving role of MRD ctDNA testing in breast cancer management and aiding in early detection of disease recurrence.

Jason Aboudi Mouabbi, MD, discussed the importance of using ctDNA testing to inform treatment decision-making across breast cancer populations.

Jason Mouabbi, MD, discusses the emerging role of ctDNA tests in breast cancer management and their use in early detection and treatment monitoring.